Further characterization of the iodide inhibitory effect on the cyclic AMP system in dog thyroid slices.
Iodide inhibits cyclic AMP accumulation in the thyroid by a process which is prevented by inhibition of iodide uptake and of thyroid peroxidase. By a similar process, it also exerts other independent effects such as the enhancement of iodinated protein release. Iodide inhibited the stimulation of adenylate cyclase by prostaglandin E1, cholera toxin and forskolin. The action of iodide was not relieved by phosphodiesterase inhibitors and was not additive with the effect of norepinephrine or adenosine. Iodide did not decrease the cellular level of ATP. The data are compatible with an inhibition of adenylate cyclase beyond the level of the receptor, presumably at the level of the catalytic unit or its interaction with the positive transducing unit NS. The effect of iodide required TSH for its expression but not for its installation. It was decreased under all conditions in which iodide organification was decreased: decreased iodide or increased methimazole concentration, absence of calcium in the medium, etc. However, the relation between iodide binding to proteins and effect was not linear. The effect was not relieved by washing in the absence of iodide and in the presence of perchlorate, but it was partly reversible in the presence of methimazole propylthiouracyl or thiourea. It was not relieved by cooling to 20 degrees C and cytochalasin b, which block stimulated thyroglobulin hydrolysis and iodothyronine release, nor by actinomycin D, cycloheximide, puromycin, mepacrine or indomethacin. The data suggest that iodide binds to a saturable cell component by a reaction which is reversible only in the presence of thiol-containing drugs.
J
J
Van Sande
P
P
Cochaux
J E
JE
Dumont
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism; D000527:Alprostadil; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002772:Cholera Toxin / Q000494:pharmacology; D005576:Colforsin; D000242:Cyclic AMP / Q000096:biosynthesis*; D004224:Diterpenes / Q000494:pharmacology; D004285:Dogs; D007454:Iodides / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D008713:Methimazole / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D014176:Protein Biosynthesis; D012313:RNA / Q000096:biosynthesis; D013961:Thyroid Gland / Q000187:drug effects / Q000378:metabolism*; D013972:Thyrotropin / Q000494:pharmacology; D014284:Triiodothyronine / Q000378:metabolism
D004224:Diterpenes; D007454:Iodides; D007457:Iodine Radioisotopes; D011458:Prostaglandins E; D014284:Triiodothyronine; D005576:Colforsin; D012368:4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; D008713:Methimazole; D012313:RNA; D000255:Adenosine Triphosphate; D013972:Thyrotropin; D002772:Cholera Toxin; D000242:Cyclic AMP; D000527:Alprostadil; D002118:Calcium; D015056:1-Methyl-3-isobutylxanthine